Press release
Investigation announced for Long-Term Investors in shares of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP)
An investigation on behalf of current long term investors in NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) shares.
Investors who are current long term investors in NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: NRXP stocks follows a lawsuit filed against NRx Pharmaceuticals, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: NRXP stocks, concerns whether certain NRx Pharmaceuticals, Inc. directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the District of Delaware the plaintiff alleges that, the Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the ZYESAMI EUA Application contained insufficient data regarding the potential benefits and risks of ZYESAMI; (ii) accordingly, the FDA was unlikely to approve the ZYESAMI EUA Application in its present form; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) have certain options and should contact the Shareholders Foundation.
Contact:
Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in shares of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) here
News-ID: 2621219 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for NRx
$40 Price Target in New H. C. Wainright Analyst Report on Leader in $3 Billion S …
Image: https://www.globalnewslines.com/uploads/2025/09/1757392285.jpg
$NRXP Continues Expansion with Completion of Dura Medical Acquisition in Network of Interventional Psychiatry Clinics
* Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain.
* Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC).
* H.C. Wainright Analyst Report Cites Paradigm Shift in the Treatment of Depression With Suicidality; Assuming Coverage…
Advancements on Multiple Fronts in $3 Billion Suicidal Depression Market, Highli …
Image: https://www.globalnewslines.com/uploads/2025/08/1755525181.jpg
$NRXP Sees 10-Fold Market Expansion to 13 Million Americans for Bipolar Depression Alone.
* Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain.
* Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC).
* FDA Fast Track Designation for NRX 100 for Suicidal Ideation in Patients with Depression, Including Bipolar Depression.
…
$3 Billion Suicidal Depression Market May Soon be Accessible via FDA Fast Track …
Image: https://www.globalnewslines.com/uploads/2025/08/1754917343.jpg
$NRXP Has $7.8 Million for Clinic Acquisitions and Purchase of Kadima Neuropsychiatry Institute as Treatment Model and Leading Investigative Site for Suicidal Depression / PTSD
* Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain.
* Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC).
* FDA Fast Track Designation for NRX…
$300 Million in Milestones Plus Tiered Double-Digit Royalties from Accepted Term …
Image: https://www.globalnewslines.com/uploads/2025/03/1742217317.jpg
$NRXP is Poised to Address Over $3 Billion Suicidal Depression Market in the US
* Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain.
* Aiming to be the First FDA-Approved Medication to Treat Suicidal Depression
* Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC).
* New Drug Application for…
NRx Pharmaceuticals Highlights Breakthrough Oral Antidepressant's Efficacy in Re …
- Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.
- June Meeting of the American Society for Clinical Psychopharmacology Focused on Intravenous Ketamine and Intranasal S-Ketamine for Severe Depression and Suicidality.
- Presenters from 3 Open Label Studies at the ASCP Suggested Intravenous Ketamine is Equivalent or has Advantages over Intranasal S-Ketamine.
- NRXP Reached 9-Month Stability Point with its Ketamine Formulation (NRX-100) and Initiated…
Final Clinical Trial Results Show Superior Safety and Efficacy for NRX-101; Plan …
Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.
MOU Signed with Conversio Health with Immediate Plans to Ship IV Ketamine Product to Full Range of Customers via 503a and 503b Pharmacies.
Clinical Trial Success in Proving a Statistically-Significant 76% Reduction in Akathisia in Participants Treated with NRX-101 Compared to Lurasidone.
Company Plans to Seek Accelerated Approval of NRX-101 for Bipolar Depression and Akathisia and Broaden…
